A-to-I RNA edited POLA2 attained carcinogenesis in PCa by impeding immune infiltration, fortifying glycolysis and upregulating BTBD7, indicating that edited POLA2 has the potential to become a tool for gene therapy. The gene discussed is BTBD7; the disease is posterior cortical atrophy.